Juvenile myelomonocytic leukemia: A report from the 2nd International JMML Symposium

Leukemia Research

Volumn 33, Issue 3, 2009, Pages 355-362

  Chan, Rebecca J ^a   Cooper, Todd ^b   Kratz, Christian P ^c   Weiss, Brian ^d   Loh, Mignon L ^e  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF FREIBURG   (Germany)

^d CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Diagnosis; Juvenile myelomonocytic leukemia (JMML); NF1; PTPN11; RAS; Therapy

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; BCR ABL PROTEIN; BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; FLUDARABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOGLOBIN F; MELPHALAN; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAS PROTEIN; RETINOIC ACID; TIPIFARNIB;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANIMAL MODEL; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CELL COUNT; CLINICAL ASSESSMENT; DISEASE FREE SURVIVAL; DRUG MEGADOSE; ENZYME ACTIVITY; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; HEMATOPOIETIC STEM CELL; HUMAN; INCIDENCE; JUVENILE MYELOMONOCYTIC LEUKEMIA; LEUKOCYTE COUNT; MOLECULAR GENETICS; MONOCYTE; MYELOID PROGENITOR CELL; ONCOGENE RAS; PRIORITY JOURNAL; SINGLE DRUG DOSE; SPLENOMEGALY; THROMBOCYTE COUNT; TREATMENT RESPONSE;

ADOLESCENT; CHILD; HUMANS; INTERNET; LEUKEMIA, MYELOMONOCYTIC, JUVENILE; NEUROFIBROMIN 1; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; RAS PROTEINS; YOUNG ADULT;

EID: 58549090093     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.08.022     Document Type: Article

References (59)

1. Emanuel P.D., Bates L.J., Castleberry R.P., Gualtieri R.J., and Zuckerman K.S. Selective hypersensitivity to granulocyte-macrophage colony-stimulating factor by juvenile chronic myeloid leukemia hematopoietic progenitors. Blood 77 (1991) 925-929
2. Freedman M.H., Cohen A., Grunberger T., Bunin N., Luddy R.E., Saunders E.F., et al. Central role of tumour necrosis factor, GM-CSF, and interleukin 1 in the pathogenesis of juvenile chronic myelogenous leukaemia. Br J Haematol 80 (1992) 40-48
3. Estrov Z., Zimmerman B., Grunberger T., Chao J., Teshima I.E., Chan H.S., et al. Characterization of malignant peripheral blood cells of juvenile chronic myelogenous leukemia. Cancer Res 46 (1986) 6456-6461
4. Altman A.J., Palmer C.G., and Baehner R.L. Juvenile chronic granulocytic" leukemia: a panmyelopathy with prominent monocytic involvement and circulating monocyte colony-forming cells. Blood 43 (1974) 341-350
5. Emanuel P.D. Juvenile myelomonocytic leukemia. Curr Hematol Rep 3 (2004) 203-209
6. Bergstraesser E., Hasle H., Rogge T., Fischer A., Zimmermann M., Noellke P., et al. Non-hematopoietic stem cell transplantation treatment of juvenile myelomonocytic leukemia: a retrospective analysis and definition of response criteria. Pediatr Blood Cancer 49 (2007) 629-633
7. Locatelli F., Nollke P., Zecca M., Korthof E., Lanino E., Peters C., et al. Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial. Blood 105 (2005) 410-419
8. Brodeur G.M. The NF1 gene in myelopoiesis and childhood myelodysplastic syndromes. N Engl J Med 330 (1994) 637-639
9. Side L., Taylor B., Cayouette M., Conner E., Thompson P., Luce M., et al. Homozygous inactivation of the NF1 gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders. N Engl J Med 336 (1997) 1713-1720
10. Shannon K.M., O'Connell P., Martin G.A., Paderanga D., Olson K., Dinndorf P., et al. Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. N Engl J Med 330 (1994) 597-601
11. Sheng X.M., Kawamura M., Ohnishi H., Ida K., Hanada R., Kojima S., et al. Mutations of the RAS genes in childhood acute myeloid leukemia, myelodysplastic syndrome and juvenile chronic myelocytic leukemia. Leukemia Res 21 (1997) 697-701
12. Kalra R., Paderanga D.C., Olson K., and Shannon K.M. Genetic analysis is consistent with the hypothesis that NF1 limits myeloid cell growth through p21ras. Blood 84 (1994) 3435-3439
13. Tartaglia M., Niemeyer C.M., Fragale A., Song X., Buechner J., Jung A., et al. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet 34 (2003) 148-150
14. Loh M.L., Vattikuti S., Schubbert S., Reynolds M.G., Carlson E., Lieuw K.H., et al. Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood 103 (2004) 2325-2331
15. Kratz C.P., Niemeyer C.M., Castleberry R.P., Cetin M., Bergstrasser E., Emanuel P.D., et al. The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease. Blood 106 (2005) 2183-2185
16. Bader J.L., and Miller R.W. Neurofibromatosis and childhood leukemia. J Pediatr 92 (1978) 925-929
17. Shannon K.M., Watterson J., Johnson P., O'Connell P., Lange B., Shah N., et al. Monosomy 7 myeloproliferative disease in children with neurofibromatosis, type 1: epidemiology and molecular analysis. Blood 79 (1992) 1311-1318
18. Bader-Meunier B., Tchernia G., Mielot F., Fontaine J.L., Thomas C., Lyonnet S., et al. Occurrence of myeloproliferative disorder in patients with Noonan syndrome. J Pediatr 130 (1997) 885-889
19. Choong K., Freedman M.H., Chitayat D., Kelly E.N., Taylor G., and Zipursky A. Juvenile myelomonocytic leukemia and Noonan syndrome. J Pediatr Hematol Oncol 21 (1999) 523-527
20. Tartaglia M., Mehler E.L., Goldberg R., Zampino G., Brunner H.G., Kremer H., et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet 29 (2001) 465-468
21. Schubbert S., Zenker M., Rowe S.L., Boll S., Klein C., Bollag G., et al. Germline KRAS mutations cause Noonan syndrome. Nat Genet 38 (2006) 331-336
22. Carta C., Pantaleoni F., Bocchinfuso G., Stella L., Vasta I., Sarkozy A., et al. Germline missense mutations affecting KRAS Isoform B are associated with a severe Noonan syndrome phenotype. Am J Hum Genet 79 (2006) 129-135
23. Roberts A.E., Araki T., Swanson K.D., Montgomery K.T., Schiripo T.A., Joshi V.A., et al. Germline gain-of-function mutations in SOS1 cause Noonan syndrome. Nat Genet 39 (2007) 70-74
24. Tartaglia M., Pennacchio L.A., Zhao C., Yadav K.K., Fodale V., Sarkozy A., et al. Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome. Nat Genet 39 (2007) 75-79
25. Pandit B., Sarkozy A., Pennacchio L.A., Carta C., Oishi K., Martinelli S., et al. Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nat Genet 39 (2007) 1007-1012
26. Razzaque M.A., Nishizawa T., Komoike Y., Yagi H., Furutani M., Amo R., et al. Germline gain-of-function mutations in RAF1 cause Noonan syndrome. Nat Genet 39 (2007) 1013-1017
27. Aoki Y., Niihori T., Kawame H., Kurosawa K., Ohashi H., Tanaka Y., et al. Germline mutations in HRAS proto-oncogene cause Costello syndrome. Nat Genet 37 (2005) 1038-1040
28. Niihori T., Aoki Y., Narumi Y., Neri G., Cave H., Verloes A., et al. Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome. Nat Genet 38 (2006) 294-296
29. Rodriguez-Viciana P., Tetsu O., Tidyman W.E., Estep A.L., Conger B.A., Cruz M.S., et al. Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome. Science 311 (2006) 1287-1290
30. Sarkozy A., Conti E., Seripa D., Digilio M.C., Grifone N., Tandoi C., et al. Correlation between PTPN11 gene mutations and congenital heart defects in Noonan and LEOPARD syndromes. J Med Genet 40 (2003) 704-708
31. Keren B., Hadchouel A., Saba S., Sznajer Y., Bonneau D., Leheup B., et al. PTPN11 mutations in patients with LEOPARD syndrome: a French multicentric experience. J Med Genet 41 (2004) e117
32. Basu T.N., Gutmann D.H., Fletcher J.A., Glover T.W., Collins F.S., and Downward J. Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature 356 (1992) 713-715
33. DeClue J.E., Papageorge A.G., Fletcher J.A., Diehl S.R., Ratner N., Vass W.C., et al. Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. Cell 69 (1992) 265-273
34. Tartaglia M., Kalidas K., Shaw A., Song X., Musat D.L., Van Der Burgt I., et al. PTPN11 mutations in Noonan Syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity. Am J Hum Genet 70 (2002) 1555-1563
35. Matsuda K., Shimada A., Yoshida N., Ogawa A., Watanabe A., Yajima S., et al. Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations. Blood 109 (2007) 5477-5480
36. Flotho C., Kratz C.P., Bergstrasser E., Hasle H., Stary J., Trebo M., et al. Genotype-phenotype correlation in cases of juvenile myelomonocytic leukemia with clonal RAS mutations. Blood 111 (2008) 966-967 [author reply 967-968]
37. Yoshida N., Yagasaki H., Yoshimi A., Takahashi Y., Xu Y., Tanaka M., et al. Correlation of clinical features with the mutational status of GM-CSF signaling pathway-related genes in children with juvenile myelomonocytic leukemia. Blood 110 (2007) 457a
38. Braun B.S., Tuveson D.A., Kong N., Le D.T., Kogan S.C., Rozmus J., et al. Shannon KM. Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proc Natl Acad Sci USA 101 (2004) 597-602
39. Largaespada D.A., Brannan C.I., Jenkins N.A., and Copeland N.G. Nf1 deficiency causes Ras-mediated granulocyte/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukaemia. Nat Genet 12 (1996) 137-143
40. Bollag G., Clapp D.W., Shih S., Adler F., Zhang Y.Y., Thompson P., et al. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat Genet 12 (1996) 144-148
41. Le D.T., Kong N., Zhu Y., Lauchle J.O., Aiyigari A., Braun B.S., et al. Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder. Blood 103 (2004) 4243-4250
42. Birnbaum R.A., O'Marcaigh A., Wardak Z., Zhang Y.Y., Dranoff G., Jacks T., et al. Nf1 and Gmcsf interact in myeloid leukemogenesis. Mol Cell 5 (2000) 189-195
43. Fornaro M., Burch P.M., Yang W., Zhang L., Hamilton C.E., Kim J.H., et al. SHP-2 activates signaling of the nuclear factor of activated T cells to promote skeletal muscle growth. J Cell Biol 175 (2006) 87-97
44. Allard J.D., Chang H.C., Herbst R., McNeill H., and Simon M.A. The SH2-containing tyrosine phosphatase corkscrew is required during signaling by sevenless, Ras1 and Raf. Development 122 (1996) 1137-1146
45. Schubbert S., Lieuw K., Rowe S.L., Lee C.M., Li X., Loh M.L., et al. Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells. Blood 106 (2005) 311-317
46. Mohi M.G., Williams I.R., Dearolf C.R., Chan G., Kutok J.L., Cohen S., et al. Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations. Cancer Cell 7 (2005) 179-191
47. Braun B.S., Cheung L.S., Chan G.G., Yang W.A., Archard J.A., Neel B.G., et al. A noncatalytic Ras-independent function of SHP-2 is essential in hematopoietic progenitors. Blood 110 (2007) 34a
48. Chan G., Kalaitzidis D., Mohi M.G., Yang W., Kutok J.L., and Neel B.G. Inducible expression of leukemia-associated Shp2 (Ptpn11) affects multiple stages of hematopoiesis and causes a fatal myeloproliferative disorder (MPD) in mice. Blood 110 (2007) 457a
49. Kotecha N., Flores N.J., Irish J.M., Simonds E., Sakai D.S., Archambeault S., Diaz-Flores E., Coram M., Shannon K.M., Nolan G.P., and Loh M.L. Single cell profiling identifies aberrant stat5 activation in myeloid malignancies with specific clinical and biologic correlates. Cancer Cell 14 (2008) 335-343
50. Archambeault S., Flores N.J., Yoshimi A., Kratz C.P., Reising M., Fischer A., et al. Development of an allele-specific minimal residual disease assay for patients with juvenile myelomonocytic leukemia. Blood 111 (2008) 1124-1127
51. Koike K., and Matsuda K. Recent advances in the pathogenesis and management of juvenile myelomonocytic leukaemia. Br J Haematol (2008)
52. Niemeyer C.M., and Kratz C.P. Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia: molecular classification and treatment options. Br J Haematol 140 (2008) 610-624
53. Yoshimi A., Mohamed M., Bierings M., Urban C., Korthof E., Zecca M., et al. Second allogeneic hematopoietic stem cell transplantation (HSCT) results in outcome similar to that of first HSCT for patients with juvenile myelomonocytic leukemia. Leukemia 21 (2007) 556-560
54. Manabe A., Okamura J., Yumura-Yagi K., Akiyama Y., Sako M., Uchiyama H., et al. Allogeneic hematopoietic stem cell transplantation for 27 children with juvenile myelomonocytic leukemia diagnosed based on the criteria of the International JMML Working Group. Leukemia 16 (2002) 645-649
55. Rowinsky E.K., Windle J.J., and Von Hoff D.D. Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development. J Clin Oncol 17 (1999) 3631-3652
56. Emanuel P.D., Snyder R.C., Wiley T., Gopurala B., and Castleberry R.P. Inhibition of juvenile myelomonocytic leukemia cell growth in vitro by farnesyltransferase inhibitors. Blood 95 (2000) 639-645
57. ®) in untreated juvenile myelomonocytic leukemia (JMML): a children's oncology group study. Blood 106 (2005) 727a
58. Iversen P.O., Emanuel P.D., and Sioud M. Targeting Raf-1 gene expression by a DNA enzyme inhibits juvenile myelomonocytic leukemia cell growth. Blood 99 (2002) 4147-4153
59. Lauchle J.O., Le D.T., Kim D., Akagi K., Gorman M.F., Tran M., et al. Mutations That cooperate with Nf1 inactivation in leukemogenesis influence therapeutic response to MEK inhibition. Blood 110 (2007) 183a